Lee's Pharmaceutical Holdings Limited (HKG:0950)
Hong Kong · Delayed Price · Currency is HKD 1.210
-0.030 (-2.42%)
Apr 2, 2026, 4:08 PM HKT
HKG:0950 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,436 | 1,400 | 1,053 | 1,233 | 1,266 | |
Revenue Growth (YoY) | 2.57% | 32.95% | -14.61% | -2.61% | 4.06% |
Cost of Revenue | 706.42 | 646.61 | 501.72 | 462.39 | 459.87 |
Gross Profit | 729.56 | 753.36 | 551.31 | 770.76 | 806.28 |
Selling, General & Admin | 556.96 | 582.59 | 492.91 | 544.88 | 663.7 |
Research & Development | 110.96 | 83.83 | 96.8 | 168.89 | 243.84 |
Other Operating Expenses | -48.8 | -60.32 | -75.72 | -70.19 | -96.41 |
Operating Expenses | 619.28 | 619.8 | 515.27 | 643.31 | 901.41 |
Operating Income | 110.28 | 133.55 | 36.04 | 127.44 | -95.13 |
Interest Expense | -11.23 | -13.82 | -11.28 | -6.62 | -4.4 |
Interest & Investment Income | 1.87 | 2.13 | 1.53 | 2.39 | 5.91 |
Earnings From Equity Investments | -1.85 | -0.84 | -0.87 | -1.1 | -3.5 |
Currency Exchange Gain (Loss) | -9.83 | 3.61 | -0.88 | -5.63 | 3.05 |
Other Non Operating Income (Expenses) | - | -0.37 | -0.62 | -0.98 | -1.32 |
EBT Excluding Unusual Items | 89.25 | 124.27 | 23.93 | 115.51 | -95.38 |
Impairment of Goodwill | -0.47 | - | - | - | - |
Gain (Loss) on Sale of Investments | 0.35 | -0.38 | -1.43 | -46.36 | 2,300 |
Gain (Loss) on Sale of Assets | -0.2 | 0.14 | 41.63 | 0.24 | 0.04 |
Asset Writedown | -16.06 | -25.91 | -33.31 | -2.68 | -235.09 |
Other Unusual Items | - | - | -0.04 | 1.15 | - |
Pretax Income | 72.89 | 98.11 | 30.79 | 67.86 | 1,969 |
Income Tax Expense | 22.27 | 29.5 | 10.84 | 22.03 | 9.48 |
Earnings From Continuing Operations | 50.62 | 68.61 | 19.95 | 45.84 | 1,960 |
Minority Interest in Earnings | 41.32 | 24.49 | -3.25 | 5.45 | 27.29 |
Net Income | 91.94 | 93.1 | 16.7 | 51.28 | 1,987 |
Net Income to Common | 91.94 | 93.1 | 16.7 | 51.28 | 1,987 |
Net Income Growth | -1.25% | 457.55% | -67.44% | -97.42% | 1436.68% |
Shares Outstanding (Basic) | 589 | 589 | 589 | 589 | 589 |
Shares Outstanding (Diluted) | 589 | 589 | 589 | 589 | 589 |
Shares Change (YoY) | 0.03% | - | - | -0.04% | 0.15% |
EPS (Basic) | 0.16 | 0.16 | 0.03 | 0.09 | 3.38 |
EPS (Diluted) | 0.16 | 0.16 | 0.03 | 0.09 | 3.37 |
EPS Growth | -1.26% | 457.53% | -67.44% | -97.42% | 1434.25% |
Free Cash Flow | - | 198.06 | 80.65 | 266.18 | 159.99 |
Free Cash Flow Per Share | - | 0.34 | 0.14 | 0.45 | 0.27 |
Dividend Per Share | 0.045 | 0.045 | 0.018 | 0.020 | 0.061 |
Dividend Growth | - | 150.00% | -10.00% | -67.21% | 5.17% |
Gross Margin | 50.81% | 53.81% | 52.35% | 62.50% | 63.68% |
Operating Margin | 7.68% | 9.54% | 3.42% | 10.33% | -7.51% |
Profit Margin | 6.40% | 6.65% | 1.59% | 4.16% | 156.94% |
Free Cash Flow Margin | - | 14.15% | 7.66% | 21.58% | 12.64% |
EBITDA | 196.99 | 220.26 | 130.62 | 237.9 | 16.83 |
EBITDA Margin | 13.72% | 15.73% | 12.40% | 19.29% | 1.33% |
D&A For EBITDA | 86.71 | 86.71 | 94.58 | 110.46 | 111.96 |
EBIT | 110.28 | 133.55 | 36.04 | 127.44 | -95.13 |
EBIT Margin | 7.68% | 9.54% | 3.42% | 10.33% | -7.51% |
Effective Tax Rate | 30.55% | 30.07% | 35.20% | 32.46% | 0.48% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.